Opportunities of using nadroparin calcium for prevention thrombotic complications at risk of coagulopathic bleeding

Abstract

An obstetrician-gynecologist faces in clinical practice cases requiring to weigh up not only benefits of administering preventive agents for venous thromboembolic complications (VTEC) but also risks related to concomitant coagulopathy. Here, we discuss issues related to using low molecular weight heparins (LMWHs) in pregnancy particularly nadroparin calcium for patients at high risk of VTEC and immune thrombocytopenia as a factor of coagulopathic bleedings.published VTEC prevention data in pregnancy and postpartum are presented. Moreover, literature review about VTEC prevention effect on pregnancy course and delivery in women with immune thrombocytopenia are discussed. A clinical case of a patient with immune thrombocytopenia and high thrombosis risk during pregnancy along with administered calcium nadroparin is described.

Keywords

• pregnancy
• thromboembolic complications
• low molecular weight heparins
• lmwhs
• calcium nadroparin
• thrombocytopenia
• blood coagulation system
• massive obstetric blood loss